Sherlock's novel CRISPR coronavirus test cleared in U.S.

By LabPulse.com staff writers

May 7, 2020 -- Engineering biology company Sherlock Biosciences has received emergency use authorization from the U.S. Food and Drug Administration (FDA) for a detection kit for the novel coronavirus using CRISPR, a gene-editing technology.

The Sherlock CRISPR SARS-CoV-2 kit uses technology that programs a CRISPR molecule to identify the presence of the virus's genetic signature from a nasal swab, nasopharyngeal swab, oropharyngeal swab, or bronchoalveolar specimen. The test is designed for CLIA-certified laboratories and can provide COVID-19 diagnostic results in about one hour, according to the company.

Sherlock is also working on developing an instrument-free handheld test for the novel coronavirus. The test, which will use Sherlock's Inspectr platform, will work similarly to an at-home pregnancy test to rapidly detect SARS-CoV-2's genetic signature.


Copyright © 2020 LabPulse.com
 

To read this and get access to all of the exclusive content on LabPulse.com, create a free account or sign in now.

Member Sign In:
MemberID or email address:  
Do you have a LabPulse.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?